Jazz Pharmaceuticals plc Earnings Recaps
Q1 2026
May 9, 2026
Jazz Pharmaceuticals shares rose 6.9% post-earnings, reflecting investor approval of better-than-expected revenue growth and encouraging commercial momentum across key product lines.
Key takeaways
- Total revenues reached a record $1.1 billion in Q1 2026, marking over 19% year-over-year growth.
- Xywav sales grew 18% to $408 million with about 16,600 active patients and 425 net patient additions.
- Epidiolex sales increased 15% to $250 million, driven by 16% volume growth and expanded adult patient reach.
- Early commercial uptake of Ziihera yielded $13 million in net sales, with preparations underway for a potential GEA launch following FDA priority review.
- Generated over $400 million in cash flow and non-GAAP adjusted EPS of $6.34, supporting ongoing R&D and business development investments.
Q3 2025
Nov 7, 2025
Jazz Pharmaceuticals achieved record revenues of over $1.1 billion in Q3 2025, fueled by strong sales across its product portfolio and two significant FDA approvals, paving the way for continued growth and strategic advancements.
Key takeaways
- Secured FDA approvals for Modeyso and Zepzelca, expanding treatment options for severe conditions.
- Strong commercial performance driven by Xywav's 11% year-over-year growth, contributing $431 million in net sales.
- Narrowed 2025 revenue guidance to $4.175 billion - $4.275 billion, reflecting confidence in future performance.
- Completed settlements in Xyrem antitrust litigation, allowing focus on strategic execution and shareholder value.
- Strengthened the pipeline with the Saniona licensing agreement for a promising epilepsy candidate, SAN2355.